GTHP News Alert Guided Therapeutics (GTHP) 0.2950 10/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Guided Therapeutics (GTHP) 0.2950 $GTHP

US Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country
M2 - Tue Sep 30, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nqkj8f/us_sales_and) has announced the addition of the "US Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country" report to their offering. This unique report provides US sales and market share estimates for major suppliers of cancer diagnostic testing products by assay and country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Companies Mentioned: Partial List - Diagnocure - Diasorin - Eiken Chemical - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio For more information visit http://www.researchandmarkets.com/research/nq..._sales_and

Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country
M2 - Tue Sep 30, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwszsk/sales_and_market) has announced the addition of the "Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country" report to their offering. This new report provides sales and market share estimates for major suppliers of cancer diagnostic testing products by assay and country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Companies Featured (Partial List) - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca/Nuvelo - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode - Diadexus - Diagnocure - DiaSorin - Eiken Chemical - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech For more information visit http://www.researchandmarkets.com/research/mw...and_market

Guided Therapeutics Announces Initial $200,000 Investment from Turkish Distributor, ITEM Medical Technologies Group
Business Wire - Mon Sep 08, 7:40AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that its Turkish distributor, ITEM Medical Technologies Group, referred to as ITEM, has committed to invest $200,000 in a private placement of Guided Therapeutics' common stock.

Guided Therapeutics to Present at Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10th
Business Wire - Thu Sep 04, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) developer of the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, today announced that it will be a featured presenter at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at the New York Palace Hotel in New York City.

Guided Therapeutics Initiates Cervical Cancer Screening Trial for LuViva(R) Advanced Cervical Scan
Business Wire - Tue Aug 19, 7:02AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it will begin enrollment this week in a multi-center clinical trial to expand claims for the LuViva(R) Advanced Cervical Scan to include front-line screening for cervical cancer.

Guided Therapeutics Reports Second Quarter 2014 Results
Business Wire - Wed Aug 13, 3:07PM CDT
--Submitted amended PMA for LuViva(R) Advanced Cervical Scan

Guided Therapeutics to Report Second Quarter 2014 Results and Hold Conference Call
Business Wire - Thu Jul 31, 2:11PM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its second quarter ended June 30, 2014 on Wednesday, August 13, 2014, after the market closes.

Guided Therapeutics Files PMA Amendment with FDA for LuViva(R) Advanced Cervical Scan
Business Wire - Fri Jul 25, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has filed an amendment to its premarket approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the LuViva(R) Advanced Cervical Scan.

Guided Therapeutics Granted Additional Key Patent for LuViva(R) Advanced Cervical Scan
Business Wire - Thu Jul 17, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that U.S. Patent and Trademark Office granted a new patent with 22 claims that support the technology behind the LuViva(R) Advanced Cervical Scan.

Guided Therapeutics' LuViva(R) Advanced Cervical Scan Awarded Mexican Regulatory Approval
Business Wire - Thu Jul 10, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that LuViva(R) Advanced Cervical Scan was approved for sale in Mexico by the Federal Commission for Protection against Health Risks (COFEPRIS).

Guided Therapeutics Second Quarter Sales to Reach $200,000; Update Timing for Amended PMA Application for LuViva(R) Advanced Cervical Scan
Business Wire - Wed Jul 02, 12:22PM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today provided anticipated sales results for its second quarter ended June 30, 2014 and also provided updated timing regarding the submittal of its amendment to its premarket approval (PMA) application for the LuViva(R) Advanced Cervical Scan.

Gene S. Cartwright of Guided Therapeutics, Inc (GTHP)-OTC bought Shares of GTHP
M2 - Thu Jun 19, 9:40AM CDT
Reported by InsiderCow.com at 2014-06-18 19:03:00 ET

Guided Therapeutics' LuViva(R) Advanced Cervical Scan Wins Prestigious Medical Design Award
Business Wire - Thu Jun 12, 7:01AM CDT
The LuViva(R) Advanced Cervical Scan was chosen as best designed new medical device of 2014 at the 17th Annual Medical Device Excellence Awards (MDEA) ceremony held Wednesday, June 11, 2014, in conjunction with the MD&M East event at the Jacob K. Javits Convention Center in New York. LuViva, a newly introduced product for the early detection of disease that leads to cervical cancer, is manufactured and sold by Guided Therapeutics, Inc. (OTCBB:GTHP) (OTCQB:GTHP).

Guided Therapeutics Submits Request for Face to Face Meeting with FDA; Receives Notification on PMA Extension for LuViva(R) Advanced Cervical Scan
Business Wire - Thu Mar 27, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company has submitted a letter requesting a face-to-face meeting with the U.S. Food and Drug Administration (FDA) in the next 60 to 90 days. This letter is in response to the September 6, 2013 letter that the company received from the FDA. Additionally, the FDA has granted the company its requested 180 day extension on the PMA filing to allow time for the meeting to occur.

Guided Therapeutics Reports Fourth Quarter and 2013 Results
Business Wire - Wed Mar 26, 3:44PM CDT
--LuViva(R) Advanced Cervical Scan momentum building with key opinion leaders; increasing number of product evaluations

HPV Screening Beneficial for Guided Therapeutics' LuViva(R) Advanced Cervical Scan in Developed Countries; No Anticipated Impact in Developing Countries
Business Wire - Tue Mar 18, 7:05AM CDT
The March 12, 2014, recommendation by a U.S. Food and Drug Administration (FDA) panel to use human papillomavirus (HPV) testing as an alternative to Pap testing for screening of women for cervical cancer has the potential to increase the need for the LuViva(R) Advanced Cervical Scan in developed countries, according to Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP). As part of its CE Mark, LuViva is already approved for use in the European Union as a triage test to be used after a positive HPV test and/or a positive Pap test.

Guided Therapeutics to Report Fourth Quarter 2013 Results and Hold Conference Call
Business Wire - Wed Mar 05, 2:40PM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its fourth quarter ended December 31, 2013 on Wednesday, March 26, 2014, after the market closes.

New Clinical Study Results of Guided Therapeutics' LuViva(R) Advanced Cervical Scan to be Presented by Key Opinion Leaders at Top International Medical Conference
Business Wire - Tue Feb 18, 7:05AM CST
The Secretary General of the International Federation for Cervical Pathology and Colposcopy (IFCPC), Dr. James Bentley, will present results of a new clinical study of the LuViva(R) Advanced Cervical Scan at the 15th World Congress for Cervical Pathology and Colposcopy, being held May 26 - 30 in London. The LuViva, a non-invasive device used to detect cervical disease instantly at the point of care, is a product of Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP).

2014 Analysis of the US Hospital Cancer Diagnostics Market
M2 - Thu Feb 13, 3:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/g5hk8t/2014_analysis_of) has announced the addition of the "2014 Analysis of the US Hospital Cancer Diagnostics Market" report to their offering. This new report contains 533 pages, 43 tables, and presents a comprehensive analysis of the US hospital cancer diagnostics market, including: - Major issues pertaining to the French hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. - Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. - Test volume and sales forecasts for 40 cancer diagnostic procedures performed in French hospitals. - Current instrumentation technologies and feature comparison of leading analyzers. - Sales and market shares of leading suppliers. - Emerging diagnostic technologies and their potential market applications. - Product development opportunities. - Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. - Business opportunities and strategic recommendations for suppliers. Key Topics Covered: Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology B. Major Current And Emerging Cancer Diagnostic Tests C. Instrumentation Review And Market Needs D. Current and Emerging Technologies US A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Growth and Major Suppliers Major Product Development Opportunities A. Reagent Kits and Test Systems/Panels B. Instrumentation C. Computers, Software and Automation D. Auxiliary Products Design Criteria for Decentralized Testing Products Alternative Market Penetration Strategies A. Internal Development B. Collaborative Arrangements C. University Contracts D. Distribution Strategies 1. Marketing Approaches 2. Product Complexity 3. Customer Preference 4. Established Suppliers 5. Emerging Suppliers 6. Major Types of Distributors 7. Market Segmentation Factor Potential Market Entry Barriers and Risks A. Market Maturity B. Cost Containment C. Competition D. Technological Edge and Limitations E. Patent Protection F. Regulatory Constraints G. Decentralized Testing Market Challenges Companies Mentioned: - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/g5...nalysis_of

2014 Analysis of the World Cancer Diagnostic Testing Market: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities
M2 - Mon Feb 10, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/r66j8d/2014_analysis_of) has announced the addition of the "2014 Analysis of the World Cancer Diagnostic Testing Market: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities" report to their offering. This new report contains 1,200 pages, 450 tables and provides forecasts for 40 tumor markers by country and market segment, as well as sales and market shares for reagent and instrument suppliers. The report is available by region, country, section, market segment and individual test: Regions: Global, Europe Countries: France, Germany, Italy, Japan, Spain, UK, USA Sections: Assays, Competitors, Instrumentation, Technologies Market Segments: Hospitals (France, Germany, Italy, Japan, Spain, UK, USA), Personalized Testing Tests: AFP, Beta-2 Microglobulin,CA Tumor Markers, CEA, Cell Surface Markers, Occult Blood, PAP, Pap Smear/HPV, PSA To purchase a DataPack that includes (test volumes, sales forecasts, supplier shares) please E-mail us. Key Topics Covered: Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology B. Major Current And Emerging Cancer Diagnostic Tests C. Instrumentation Review And D. Current and Emerging Technologies Competitive Profiles - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - Biomedical Diagnostics - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila - bioMerieux For more information visit http://www.researchandmarkets.com/research/r6...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 248

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 348

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 488

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Energy Management with ETB Controller from Energy Toolbase

Updated Category News Views 72

Energy Toolbase Reveals New Branding for Energy Management System Energy Toolbase has made a significant leap in the energy management sector by rebranding its energy storage control software, Acumen EMS™, to ETB Controller. This transformation marks a pivotal moment for the company as they strive to clarify the product's purpose and enhance user understanding. The ETB...

Continue Reading
FICO Achieves Silver Recognition in Analytics at 2024 IT Awards

Updated Category News Views 37

FICO Receives Silver Award for Analytics in 2024 IT Awards In a notable recognition of excellence, global analytics software leader FICO has earned the Silver Award in the Analytics category at the prestigious IT Awards for this year. Organized by Vogel IT-Media, these awards celebrate remarkable achievements and innovations within the IT sector, reflecting the industry's...

Continue Reading
Opera Limited Announces $0.40 Cash Dividend for Shareholders

Updated Category News Views 124

Opera Limited Announces Cash Dividend Opera Limited (NASDAQ: OPRA), a prominent developer in the browser market, has recently shared exciting news regarding its dividend program. The company’s Board of Directors has approved a semi-annual cash dividend of $0.40 per share. This dividend will be available to shareholders holding the company’s ordinary shares and...

Continue Reading
Revolutionizing IT Operations: JetPatch Unveils Version 5.0

Updated Category News Views 162

Revolutionizing IT Operations: JetPatch Unveils Version 5.0 New Capabilities Supercharge Patch Management and Streamline Enterprise Efficiency JetPatch, a leading innovator in enterprise IT operations, has revealed its most significant software release to date, which marks a major step forward in how organizations manage their servers, endpoints, and agents throughout...

Continue Reading
Revolutionizing Customer Billing: Ericsson and Wipro's Success

Updated Category News Views 97

Transformed Billing Experience for Odido Customers Ericsson (NASDAQ: ERIC) and Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) have successfully reshaped the billing landscape for Odido's mobile customers in the Netherlands. By adopting the cloud-native Ericsson Billing platform, hosted on Amazon Web Services (AWS), Odido can now offer cutting-edge 5G services along...

Continue Reading